News

David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.

Researchers find that targeted subretinal delivery of stem cell derived RPE to geographic atrophy is feasible 

The study finds that treatment resulted in a significant visual improvement.

‘From the Bench to Bedside and Back’ is focal point for this year’s conference

Inhibition plays role in autoimmune-based inflammation; has unique mechanism of action

Group of researchers aim to validate both approaches in proof-of-concept study

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Quiescence, steroid-free quiescence achieved in VISUAL III trial

FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder